LL

April 19, 2018
Published by LL at April 19, 2018
Categories

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

[…]
Do you like it?0
Read more
December 22, 2017
Published by LL at December 22, 2017
Categories

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

[…]
Do you like it?0
Read more
October 5, 2015
Published by LL at October 5, 2015
Categories

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

[…]
Do you like it?0
Read more
August 31, 2015
Published by LL at August 31, 2015
Categories

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

[…]
Do you like it?0
Read more
1234
Next page